

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.

<http://hdl.handle.net/2066/124865>

Please be advised that this information was generated on 2017-12-05 and may be subject to change.



Editor's choice
Scan to access more
free content

ORIGINAL ARTICLE

GATAD2B loss-of-function mutations cause a recognisable syndrome with intellectual disability and are associated with learning deficits and synaptic undergrowth in *Drosophila*

Marjolein H Willemsen,¹ Bonnie Nijhof,^{1,2,3} Michaela Fenckova,^{1,2,3} Willy M Nillesen,¹ Ernie M H F Bongers,¹ Anna Castells-Nobau,^{1,2,3} Lenke Asztalos,⁴ Erika Viragh,⁵ Bregje W M van Bon,¹ Emre Tezel,^{1,2,3} Joris A Veltman,^{1,2,6} Han G Brunner,^{1,6} Bert B A de Vries,^{1,6} Joep de Ligt,^{1,2,6} Helger G Yntema,¹ Hans van Bokhoven,^{1,2,3} Bertrand Isidor,⁷ Cédric Le Caignec,⁷ Elsa Lorino,⁸ Zoltan Asztalos,^{4,5,9} David A Koolen,¹ Lisenka E L M Vissers,^{1,2,6} Annette Schenck,^{1,2,3} Tjitske Kleefstra^{1,3,6}

For numbered affiliations see end of article.

Correspondence to

Dr Tjitske Kleefstra and Dr Annette Schenck, Department of Human Genetics, Radboud University Medical Centre, PO Box 9101, Nijmegen 6500 HB, The Netherlands; t.kleefstra@gen.umcn.nl; a.schenck@gen.umcn.nl

MHW, BN, MF, AS and TK contributed equally.

Received 19 December 2012

Revised 28 March 2013

Accepted 8 April 2013

Published Online First

4 May 2013

ABSTRACT

Background GATA zinc finger domain containing 2B (*GATAD2B*) encodes a subunit of the MeCP1-Mi-2/nucleosome remodelling and deacetylase complex involved in chromatin modification and regulation of transcription. We recently identified two de novo loss-of-function mutations in *GATAD2B* by whole exome sequencing in two unrelated individuals with severe intellectual disability.

Methods To identify additional individuals with *GATAD2B* aberrations, we searched for microdeletions overlapping with *GATAD2B* in inhouse and international databases, and performed targeted Sanger sequencing of the *GATAD2B* locus in a selected cohort of 80 individuals based on an overlap with the clinical features in the two index cases. To address whether *GATAD2B* is required directly in neurones for cognition and neuronal development, we investigated the role of *Drosophila* *GATAD2B* orthologue *simjang* (*simj*) in learning and synaptic connectivity.

Results We identified a third individual with a 240 kb microdeletion encompassing *GATAD2B* and a fourth unrelated individual with *GATAD2B* loss-of-function mutation. Detailed clinical description showed that all four individuals with a *GATAD2B* aberration had a distinctive phenotype with childhood hypotonia, severe intellectual disability, limited speech, tubular shaped nose with broad nasal tip, short philtrum, sparse hair and strabismus. Neuronal knockdown of *Drosophila* *GATAD2B* orthologue, *simj*, resulted in impaired learning and altered synapse morphology.

Conclusions We hereby define a novel clinically recognisable intellectual disability syndrome caused by loss-of-function of *GATAD2B*. Our results in *Drosophila* suggest that *GATAD2B* is required directly in neurones for normal cognitive performance and synapse development.

INTRODUCTION

Intellectual disability (ID) is a group of disorders with an extremely heterogeneous clinical and genetic presentation. More than 500 ID genes have

been identified and many more await discovery. This large number of ID genes is believed to converge onto a limited number of common underlying pathways and processes.¹ Several ID genes encode proteins that are involved in chromatin modification.^{1,2}

Since the recent advent of next generation sequencing technology, whole exome sequencing (WES) has been successfully applied to the identification of genes for clinically established ID syndromes.^{3–6} In addition, family based WES was successful in elucidating causative de novo gene mutations in sporadic individuals who do not present with a recognisable syndrome.^{7–9} However, exploration of the pathogenicity of mutations in genes not previously associated with ID remains challenging. To establish a conclusive molecular diagnosis, it is therefore required to detect mutations in the same candidate genes in additional individuals with similar phenotype.¹⁰ Moreover, additional evidence and insights into functional properties of novel genes are desirable and can be obtained through studies in cell or animal models.

By application of trio based WES, we recently reported the identification of 22 candidate genes for ID.⁸ Among these was the GATA zinc finger domain containing 2B (*GATAD2B*) gene (NM_020699.2). In this gene, we identified two loss-of-function mutations in two unrelated individuals (c.584dupT; p.(Asn195fs) and c.1408 C>T; p.(Gln470*)). *GATAD2B* encodes p66beta, a subunit of the transcription repressor complex MeCP1-Mi-2/nucleosome remodelling and deacetylase (NuRD), responsible for silencing of methylated DNA by nucleosome remodelling and histone deacetylation.^{11,12}

Here, we report an additional individual with a disruptive *GATAD2B* mutation (c.565_566del; p.(Gln190fs)), representing the third loss-of-function mutation in this gene. The mutation was revealed by direct Sanger sequencing in a selected cohort of 80 individuals with overlapping features comprising ID, childhood hypotonia and an abnormal shape of the nose (including a tubular shape, prominent and

To cite: Willemsen MH, Nijhof B, Fenckova M, et al. *J Med Genet* 2013;**50**: 507–514.

broad base of the nose). In addition, we found a fourth individual with a 240 kb *de novo* microdeletion encompassing *GATAD2B*. Comparison of the phenotype of all four individuals revealed a remarkable overlap in clinical presentation.

Modelling of the *Drosophila* orthologue of *GATAD2B* loss-of-function confirms its role in cognition and shows a critical role of *GATAD2B* in synapse development. Together, our data establish a novel ID syndrome. It adds to the growing list of ID conditions that are caused by mutated genes involved in chromatin remodelling that can shed light onto the epigenetic control of cognition.

METHODS

Patients

Individuals 1 and 2 were ascertained through family based WES studies recently reported by our group^{7,8} (trio 4 in Vissers *et al*⁷ and trio 69 in Ligt *et al*⁸ respectively). The *GATAD2B* mutation in individual 1 was noticed in retrospect upon reanalysis of the sequencing data, after the detection of the mutation in individual 2.

Subsequently, we searched for individuals with small microdeletions overlapping with *GATAD2B* in our inhouse database and international databases, including the database of the European Cytogeneticists Association Register of Unbalanced Chromosome Aberrations (ECARUCA) and the Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources (Decipher).

In addition, we selected a cohort of 80 individuals guided by phenotypic overlap with individuals 1 and 2. This cohort was selected based on the presence of severe ID (IQ \leq 50), limited speech ability, childhood hypotonia and facial features including abnormal shaped nose (large/prominent nose, full nose tip, tubular shaped/pear-shaped nose, broad base of the nose). All individuals had been referred to the Department of Human Genetics of the Radboud University Medical Centre in Nijmegen, the Netherlands, for genetic diagnostic evaluation of unexplained ID/developmental delay. Their parents/legal representatives consented to this study. The study was approved by the local ethical committee.

Mutation screening

Targeted Sanger sequencing of *GATAD2B* (NM_020699.2) was performed using standardised methods. Primers are available upon request. The mutation in individual 4 and the low grade mosaic in her mother were confirmed with a second independent primer pair.

Fly stocks and maintenance

Fly stocks were kept on standard *Drosophila* diet (cornmeal/sugar/yeast) at 25°C and 45%–60% humidity at 12 h light–dark cycle. Flies were reared at 25°C, 70% humidity for habituation experiments and real-time PCR, and at 28°C, 60% humidity to evaluate synapse morphology. *Simjang* (*Simj*) (CG32067) is the *Drosophila* orthologue of *GATAD2B* (Ensembl, see also Results section). An inducible RNA interference (RNAi) line against *simj* (vdrckK100285, a line with the highest specificity score, $s_{19}=1$) and its corresponding control line (vdrckK60100) were obtained from Vienna *Drosophila* RNAi Center (<http://www.vdrck.at>). RNAi was induced by the UAS-Gal4 system using a panneuronal *elav-Gal4* driver or a ubiquitous *actin-Gal4* driver obtained from the *Drosophila* Bloomington Stock Center (<http://flystocks.bio.indiana.edu/>). Line *w*¹¹¹⁸; *2xGMR-wIR*; *elav-Gal4*, *UAS-Dicer2* used in habituation experiments was produced by recombination of two independent insertions of *GMR-wIR* on chromosome II and recombination of one copy of

elav-Gal4 and *UAS-Dicer2* insertions on chromosome III. The *w*¹¹¹⁸; *UAS-Dicer2*; *elav-Gal4* driver was used to study synapse morphology, and a *w*¹¹¹⁸; *actin-Gal4/CyOGFP* driver to generate homogeneous knockdown material for real-time PCR.

Light-off jump reflex habituation

The light-off jump reflex habituation assay was performed as previously described¹³ with minor adaptations to the protocol. Briefly, 3–7-day-old individual male flies were tested for jump response in two independent 16-unit light-off jump reflex habituation systems. A total of 32 flies (16-flies/system) were simultaneously exposed to series of 100 short (15 ms) light-off pulses with a 1 s interval between the pulses. The noise amplitude of wing vibration following every jump response was recorded for 500 ms after the start of pulse and a carefully chosen threshold was applied to distinguish the jump response. Data were collected and analysed by custom-made Labview Software (National Instruments). High initial jumping response to light-off pulse decreased with growing number of trials and flies were considered habituated when they failed to jump in five consecutive trials (non-jump criterion). Habituation was scored as the number of trials required to reach the non-jump criterion (Trials To Criterion (TTC)). Mean TTC values of eight independent groups of 16 flies (tested on four different days) were compared with mean TTC values of control flies using one-way Analysis of variance (ANOVA) with correction for different experimental day and system.

Drosophila synapse morphology

Type 1b neuromuscular junctions (NMJs) at muscle 4 were analysed after dissection of L3 larvae and fixation in 3.7% paraformaldehyde (PFA) for 30 min. Preparations were colabelled for bruchpilot (*brp*) and discs large 1 (*dlg1*). *Brp* was visualised using the primary antibody nc82 (1 : 125) (Developmental Studies Hybridoma Bank, University of Iowa) applied overnight at 4°C, and a secondary Alexa 488-labelled goat-antimouse antibody (1 : 500) (Invitrogen). Discs large was visualised using the primary antibody anti-*dlg1* (1 : 25) (Developmental Studies Hybridoma Bank) in combination with the Zenon Alexa Fluor 568 Mouse IgG1 labelling kit (Invitrogen). NMJ pictures were obtained using a Leica automated brightfield multi-colour epifluorescent microscope. Individual synapses were imaged and the muscle area, NMJ area, perimeter, length, branching pattern and amount of active zones were quantitatively assessed using an inhouse developed macro.

Analysis of *simj* mRNA levels by real-time PCR

Total RNA from 3rd instar larvae was isolated using RNeasy Lipid Tissue Mini Kit (Qiagen). RNA was treated with DNase (DNasefree Kit, Ambion). First strand cDNA synthesis was performed using the Moloney Murine Leukemia Virus (M-MLV) Reverse Transcriptase (Life Technologies) and oligo(dT) primer. Gene expression was analysed by real-time PCR (7900HT Fast Real-Time PCR system, Applied Biosystems). PCR reactions were performed in a volume of 25 μ l containing 150 nM primers and GoTag Green Mastermix (Promega). Primer sequences used for amplification of *simj* were 5'-CAGCACCATTCCGTTGTG-3' (forward primer) and 5'-GCCTTGAGTGCCTTCTTCAC-3' (reverse primer). A *PolII* amplicon was used as an internal standard. *PolII* primer sequences were 5'-TCAGAGTCCGCGTAA CACC-3' (forward primer) and 5'-TGGTCACAAGTGGCTTCA TC-3' (reverse primer).

RESULTS

Clinical phenotype description

We here report the detailed clinical description of four affected individuals. Individual 1 (figure 1A–D) was born after 36 weeks and 5 days of pregnancy with a normal birth weight and no major complications upon delivery. At 2 years of age, her parents consulted a paediatrician because of global developmental delay. She could sit and crawl at the age of 16 months and stand at the age of 18 months. Hypotonia was noticed. After the age of 2 years she spoke her first words. An ophthalmologist was consulted because of strabismus. At the age of 3 years and 8 months she was able to speak about 30 single words, but her comprehension of language was at a higher level. She had a normal height (100 cm, 30th centile) and head circumference (47.5 cm, 10th centile). Her facial features included thin blond hair, narrow palpebral fissures, periorbital fullness, a tubular shape of the nose with full nasal tip, a short philtrum, thin upper lip, broad mouth and grimacing facial expression. Three years later, at the age of 6 years and 7 months she had severe developmental delay with verbal skills more severely impaired than motor skills. Her height

was normal (118.5 cm, 16th centile) and she had a low to normal head circumference (48 cm, 2nd centile). Long fingers and toes with broad distal phalanges were observed.

Individual 2 (figure 1E–H) was born with intrauterine growth retardation. Her birth weight was 2780 g at 42 weeks of pregnancy (<2nd centile). At 3 months of age a developmental delay was noticed. She could walk independently at the age of 3 years. From 8 years on, she could speak single words. Behaviour was characterised by tics and wandering during the night. Her pain threshold was elevated. Vision was impaired due to hypoplasia of the optic nerve. Upon clinical evaluation at the age of 34 years she was diagnosed with severe ID. At that time, height and head circumference were normal (both >16th centile). She had thin blond hair, deeply set eyes, narrow and upward slanting palpebral fissures, strabismus, a tubular shape of the nose with broad nasal tip, and a large mouth with short philtrum and thin upper lip. She grimaced. Her fingers were long, thin and slightly tapering.

Individual 3 (figure 1I,J) was born after an uncomplicated pregnancy of 40 weeks duration, with a low-normal birth weight



Figure 1 Facial features of individuals 1–4. Individual 1 at the age of 3 years and 8 months (A and B) and 6 years and 7 months (C and D). Individual 2 at the age of 5 years (E), at older childhood age (F) and at age 35 years (G and H). Individual 3 at the age of 3 years (I and J), and individual 4 at the age of 12 years (M and N) and younger ages (K and L). Note the similarity in facial features, comprising thin, blond hair, broad forehead, hypertelorism, periorbital fullness, deeply set eyes and narrow palpebral fissures, a short philtrum, large, tubular shaped nose with broad nasal tip, broad mouth, strabismus, and remarkable grimacing facial expression in individuals 1, 2 and 4. Access the article online to view this figure in colour.

and a normal head circumference. In the neonatal period she presented with hypotonia and feeding difficulties. Her psychomotor development was delayed. She learnt to walk without support at the age of 2 years and 9 months. At the age of 3 years speech was severely delayed with only two to three disyllabic words. Her behaviour was characterised by low frustration tolerance. Medical problems included hypermetropia and strabismus and she had shown one episode of absence epilepsy. At the age of 3 years she had a height of 90 cm (5th centile), and a head circumference of 51 cm (84th centile). Facial dysmorphism included hypertelorism, a broad forehead, a broad and flat nasal bridge and a full square tip of the nose. She had thin, blond hair.

Individual 4 (figure 1K–N) was born after 42 weeks of pregnancy with a normal birth weight. Birth was uncomplicated. She was hypotonic and passive in the neonatal period. From the beginning on, psychomotor development was delayed with poor contact making. She learned to walk from the age of 2 years and started to speak during her third year. Her speech slowly developed, and at the age of 12 years she could only speak six single words. Her behaviour was characterised by hyperactivity, inappropriate laughter, obsession for shiny and reflecting objects and mild self-mutilation. Melatonin treatment was given for sleep problems. Medical problems included intermittent divergent strabismus and hypermetropic astigmatism, and persistent constipation. Around the age of 2–3 years absence epilepsy was

suspected, but electroencephalography revealed no abnormalities. Upon physical examination at the age of 12 years and 2 months she had a height of 156 cm (50th centile), a weight of 43 kg (16th–50th centile) and a head circumference of 56.2 cm (80th–90th centile). Facial dysmorphism included a broad forehead, a broad nasal bridge with full nose tip, a broad mouth with wide-spaced central incisors, short philtrum and long palpebral fissures. She had thin, blond hair. Her fingers were long and she had fleshy hands.

Mutation detection

Individual 1 showed no abnormalities on 250K Singly Nucleotide Polymorphism (SNP) array analysis, screening for Fragile X syndrome, a metabolic screen in blood and urine, and MRI imaging of the brain. Family based WES revealed a de novo frameshift mutation in *GATAD2B* (c.584dup; p.(Asn195fs); figure 2A). This mutation is located in the central part of the gene close to the conserved region 1 (CR1) domain (figure 2D).⁸ Likewise, individual 2 did not show any abnormality on 250K SNP array analysis and a metabolic screen. Methylation tests of the Angelman syndrome related region were normal. Family based exome sequencing revealed a de novo mutation in *GATAD2B* (c.1408 C>T; p.(Gln470*); figure 2B). This mutation is located in the conserved region 2 (CR2) domain (figure 2D).⁸




Figure 2 BAM files and results of Sanger sequencing in individuals 1, 2 and 4 and their parents. Validation and de novo testing for the candidate de novo mutations in GATA zinc finger domain containing 2B (*GATAD2B*) in individuals 1 and 2, and direct sequencing of the 11 coding exons of *GATAD2B* in the cohort of individuals with phenotypic overlap, including individual 4, were performed using standard Sanger sequencing approaches. Primer sequences and PCR conditions are available upon request. (A and B) show the BAM files and the Sanger sequences of individuals 1 and 2, and (C) Sanger sequences of individual 4. Sequences of both parents of individuals 1 and 2 and the mother of individual 4 are shown as well. The mother of individual 4 carries the mutation in low mosaic state (<10%). (D) illustrates the relative positions of the mutations of individuals 1, 2 and 4 in the *GATAD2B* protein. CR1, conserved region 1; CR2, conserved region 2. Access the article online to view this figure in colour.

Individual 4 was previously investigated for mutations in the genes *FMRI*, *MECP2*, *TCF4*, *RAI1* and *UBE3A*, all showing normal results. Methylation tests of the Angelman syndrome related region and a metabolic screen gave also normal results. Conventional G-banded karyotyping yielded a maternally-inherited apparently balanced translocation between chromosomes 1q21.3 and 9q13. Further 250K SNP array analysis did not show any imbalances of these regions. Targeted sequencing of *GATAD2B* based on phenotypic overlap with the first two individuals led to the identification of a frameshift mutation (c.565_566del; p.(Gln190fs); figure 2C). This mutation is located at the border of the CR1 domain (figure 2D). The healthy mother carried the *GATAD2B* mutation in a low mosaic level, which was estimated to be below 10% in peripheral blood lymphocytes (figure 2C). The mother is highly educated and works as a social worker. She has no facial dysmorphism.

Copy number variation detection

Array comparative genomic hybridisation (CGH) analysis in individual 3 by a 60 K Agilent array, using the International Standards for Cytogenomic Arrays (ISCA) design, revealed a 240 kb de novo deletion of chromosome 1q21.3 encompassing 10 genes, including *GATAD2B* (chr1:153 893 110–154 132 780, Hg19). The distal breakpoint disrupts *GATAD2B*. The deleted region encompasses no known disease associated genes. The deletion was confirmed by Fluorescent in situ Hybridisation (FISH) with the RP11-422P24 probe. Segregation analysis in the parents was done by FISH analysis and showed that the deletion had occurred de novo.

Analysis of *GATAD2B* orthologue in *Drosophila*

To obtain independent evidence for the involvement of *GATAD2B* in the ID phenotype of the described individuals, we decided to study its function in an intact nervous system, using *Drosophila* as a model. The *Drosophila* genome contains a single orthologue of the two closely related human *GATAD2A* and *GATAD2B* genes, named *simjang* (*simj*). *Drosophila simj* has been shown to modify Wnt signalling and, like both its human counterparts, to associate with the MeCP1-Mi-2–NuRD repressor complex.¹⁴

Neuronal knockdown of *Drosophila GATAD2B* orthologue results in impaired learning

Null mutations of *Drosophila simj* have previously been reported to be lethal,¹⁴ which precluded assessment of cognitive function in adult flies. We therefore targeted expression of *simj* specifically

in *Drosophila* neurones using the UAS-Gal4 system in combination with inducible RNAi¹⁵ and examined the role of *simj* in habituation. Habituation is a form of non-associative learning where the probability of a behavioural response decreases with repeated presentations of a stimulus.¹⁶ Habituation was previously shown to be defective in classic learning and memory mutants and in a *Drosophila* model of ID.^{2 17 18}

To induce a panneuronal knockdown of *simj*, flies carrying an inducible UAS-RNAi insertion against *simj* (vdrckK100285) were mated to flies carrying the neuronal promoter element *elav-Gal4* driver. The promoter line further carried one copy of UAS-dicer2 to enhance the RNAi-mediated knockdown and two insertions of GMR-wIR to reduce the eye colour as required in our assay. Male progeny of knockdown (*simj*-RNAi) and control flies was exposed to 100 short light-off stimuli (trials) at 1 s inter-trial intervals and scored for a jump response. Flies were considered to have habituated once they failed to jump in five consecutive trials (no-jump criterion). Habituation was scored as the number of trials required to reach the no-jump criterion (TTC). Both genotypes showed wt-like initial jump responses. Control flies quickly habituated to the light-off stimuli and reduced jumping. We found that *simj*-RNAi flies habituate slower and maintain a higher jump response throughout the entire course of the experiment (figure 3A). The mean TTC of *simj*-RNAi flies was 1.7-fold higher compared with their genetic background controls (figure 3B, $p=0.007$), validating a significant deficit in habituation.

GATAD2B is required for synaptic development in *Drosophila*

Synaptic connectivity is essential for learning and for other cognitive processes.¹ We therefore addressed a possible function of *simj* in synaptic development of the larval NMJ, a well-established synaptic model system that shares major features with central excitatory synapses in the mammalian brain¹⁹ and has been successfully used to investigate human ID disorders.^{20–22} As in our habituation experiment, we investigated the *Drosophila* NMJ architecture upon panneuronal knockdown of *simj*. The synaptic and subsynaptic organisation was visualised by coimmunolabelling against *dlg1* (α -dlg1), a major scaffolding component of larval NMJs and member of the membrane-associated guanylate kinase subfamily, and anti-brp (α -brp, nc82), an integral part of active zones.²²

Neurone-specific *simj* knockdown resulted in an NMJ undergrowth phenotype (figure 4A,B), with a consistent decrease in synaptic area ($p=0.0028$), perimeter ($p=9.5e^{-005}$) and length




Figure 3 Impaired habituation of neurone-specific knockdown of *Drosophila* GATA zinc finger domain containing 2B orthologue *Simjang* (*simj*). Habituation was measured in *simj* knockdown (UAS-*simj*^{RNAi100285}/2xGMR-wIR; *elav-Gal4*, UAS-Dicer2/+, red squares) and control males (2xGMR-wIR/+; *elav-Gal4*, UAS-Dicer2/+, black circles). Jump response was induced by repeated light-off pulses for 100 trials with 1 s inter-trial interval. y Axis represents the average jump response whereas x axis represents number of trials. Habituation was significantly slower for *simj* knockdown flies (red bar, Trials To Criterion (TTC)=35.70) than for control flies (black bars, TTC=21.17). (***) indicates a significant difference ($p<0.01$) based on one-way ANOVA (B). RNAi, RNA interference. Access the article online to view this figure in colour.




Figure 4 Synapse morphology of neuromuscular junctions (NMJs) was studied in *Simjang* (*simj*) knockdown flies (UAS-*simj*^{RNAi100285}/UAS-Dicer2; *elav-Gal4/+*) (A). NMJs were visualised with coimmunolabelling against discs large 1 (A, upper panel) and *brp* (A, middle panel) and quantitatively assessed by computer-assisted analysis (A, lower panel and B). *Simj*-RNA interference (RNAi) NMJs show a decrease in NMJ area ($n=27$, $p=0.0028$), perimeter ($n=27$, $p=9.5e^{-005}$), length ($n=28$, $p=5.7e^{-008}$), the amount of branches ($n=28$, $p=0.041$) and branching points ($n=28$, $p=0.021$) and the amount of active zones ($n=25$, $p=0.0010$). The area of the muscle remained normal ($n=28$, $p=0.077$). For this plot, red bars represent the mean of each parameter of *Simj*-RNAi NMJs normalised by the mean of each parameter of the control set (black bars). Error bars indicate the normalised standard error of the mean, p, p values (two-sided t test); n, number of quantified NMJs. (*) indicates a significant difference ($p<0.05$), (**) indicates a significant difference ($p<0.01$), (***) indicates a significant difference ($p<0.001$). Access the article online to view this figure in colour.

($p=5.7e^{-008}$). *Simj*-RNAi synapses also exhibited a lower number of branches ($p=0.041$) and branching points ($p=0.021$). Last, *simj*-RNAi synapses showed a lower number of pre-synaptic sites for neurotransmitter release. Muscle size was not affected, which excludes a general growth/developmental problem. We validated the potency of the used RNAi line to induce *simj* knockdown by real-time PCR. The level of *simj* mRNA was efficiently downregulated to 29% upon induction by a ubiquitous actin-Gal4 driver ($p=0.0024$; two-tailed t test). We conclude that reduced levels of the *GATAD2B* orthologue *simj* affect learning and synapse development.

DISCUSSION

In this study, we report a novel clinically recognisable syndrome characterised by severe ID, limited speech, childhood hypotonia, thin hair and recognisable facial features, including a typical, tubular shaped nose with broad tip, deeply set eyes, broad forehead, short philtrum, broad mouth, grimacing facial expression, strabismus and long fingers caused by haploinsufficiency of *GATAD2B*. We recently identified by family based exome sequencing disruptive *GATAD2B* mutations in two individuals with overlapping phenotype.⁸ We traced a third individual with a small microdeletion encompassing *GATAD2B* showing a very similar phenotype. Though we cannot fully exclude a contribution of the nine other genes in the deleted region of this individual, the important phenotypic overlap with individuals 1 and 2 highly suggests that deletion of *GATAD2B* is the major causal factor in the phenotype of this individual. Moreover, this further confirms the role of *GATAD2B* in a recognisable syndrome with ID represented by the present individuals. To ultimately further establish a novel ID syndrome, we selected a cohort of 80 unsolved similarly affected individuals based on clinical overlap. Targeted Sanger sequencing of the *GATAD2B* locus revealed an additional patient carrying a frameshift *GATAD2B* mutation, presumably causing loss-of-function.

We noticed that *GATAD2B* is located in the chromosomal region 1q21.3 where the breakpoint of the balanced translocation that was previously found in individual 4 and her healthy mother is also located. Although this finding might be coincidental, it raised the question whether the mother carried a mosaic translocation and whether the translocation breakpoint predisposed to the deletion of two base pairs in *GATAD2B*. We

therefore performed additional FISH analysis with the region 1q23.1 specific probe RP11-216N14 that covers the *GATAD2B* gene. This showed in all 29 evaluated cells a normal pattern, indicating that the translocation breakpoint is located distally from the *GATAD2B* region. Therefore, we concluded that this does not support a correlation between the mutation in *GATAD2B* and the balanced translocation.

Complementary functional studies of the *Drosophila* *GATAD2B* orthologue *simj* demonstrated a role for the evolutionarily conserved *GATAD2B* gene family in neurodevelopmental processes. The identified habituation defect in *simj*-RNAi flies demonstrates that the *GATAD2B* orthologue is required for non-associative learning. Furthermore, evaluation of synaptic morphology revealed an NMJ undergrowth phenotype with reduced number of active zones, suggesting a critical role for *simj* and *GATAD2B* in synaptic growth and function. Whether these may contribute to or cause the observed learning defects in flies and cognitive deficit in the humans remains to be determined.

Mutations in several recently identified genes involved in chromatin modification give rise to ID syndromes, such as the 17q21.31 microdeletion/Koolen-De Vries syndrome (KDVS (MIM 610443)),^{23 24} Coffin-Siris syndrome^{13 25} (CSS (MIM135900)), Nicolaidis-Baraitser syndrome^{26 27} (NCBRS (MIM 601358)), Kleefstra syndrome^{2 28} (MIM 610253), Wiedemann-Steiner syndrome²⁹ (WDSTS (MIM 605130)) and Ohdo syndrome Say-Barber-Biesecker variant³⁰ (SBBYSS (MIM 603736)).

GATAD2B encodes p66beta, which is a subunit of the transcription repressor complex MeCP1-Mi2-NuRD that silences methylated DNA by nucleosome remodelling and histone deacetylation. This enzyme complex also comprises its close paralogue p66alpha (encoded by *GATAD2A*), the histone deacetylases HDAC1 and HDAC2, two histone binding proteins RbAp46 and RbAp48, the methyl binding domain protein 3 (MBD3), two histone modifier proteins, MTA1 and MTA2, and nucleosome remodelling factor Mi-2.¹¹ It is thus conceivable that additional genes from the MeCP1-Mi2-NuRD complex, such as *GATAD2A*, are involved in phenotypes overlapping with the here defined novel syndrome caused by *GATAD2B* mutations. P66beta and its paralogue, p66alpha, function synergistically and recruit the Mi-2-NuRD complex to its target sites. They interact with methyl-CpG bound MBD2 and with

non-acetylated histones to assemble in the so-called MeCP1 repressor complex.¹¹ It has been shown that p66alpha and p66beta, and particularly their highly conserved CR1 and CR2 domains, are crucial for complex formation and mediated gene silencing.¹² Furthermore, homozygous loss-of-function of p66alpha in mice resulted in an embryonic lethal phenotype with severe global malformations, growth retardation and necrosis. Heterozygous mice were viable and appeared normal, but detailed (neurological) phenotyping was not performed.³¹

We recently used the powerful strategy of combining human genetic studies and *Drosophila* modelling to provide a novel chromatin remodelling module that underlies Kleefstra syndrome spectrum.² Similar to that, we find a strikingly high conservation between human and *Drosophila* NuRD complexes, with all complex components being present in fly.³² As additional variants in human NuRD complex genes will arise, it will be straightforward to validate their significance. Our data add *GATAD2B*, and possibly the whole MeCP1-Mi2-NuRD complex, to the growing list of ID genes involved in chromatin remodelling.

Author affiliations

¹Department of Human Genetics, Radboud University Medical Centre, The Netherlands

²Nijmegen Center for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands

³Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Centre, Nijmegen, The Netherlands

⁴Department of Genetics, Aktogen, University of Cambridge, Cambridge, UK

⁵Institute of Biochemistry, Biological Research Center, Hungarian Academy of Sciences, Szeged, Hungary

⁶Institute for Genetic and Metabolic Disease, Radboud University Medical Centre, Nijmegen, The Netherlands

⁷Service de Génétique Médicale, CHU Nantes, Nantes, France

⁸Service de Pédiatrie, CHU Nantes, Nantes, France

⁹Aktogen Hungary Ltd., Biological Research Center, Hungarian Academy of Sciences, Szeged, Hungary

Acknowledgements We thank the participating individuals and their families. We also thank Suzanne Vloet-Keijzer and Martine Ruiterskamp for their technical assistance with the targeted Sanger sequencing.

Contributors The study was designed and the results were interpreted by MHW, TK, BN, MF, ZA, LA, AC-N, EV, AS, LELMV, HGB, HvB and JAV. Subject ascertainment and recruitment were carried out by MHW, TK, BMWvB, DAK, EMHFB, BI, CLC, EL and BBAdV. Sequencing and genotyping were carried out and interpreted by WMN, HGY, LELMV, JdL and JAV. The manuscript was drafted by MHW, BN, MF, TK and AS. All authors contributed to the final version of the paper.

Funding This work was supported by grants from the Consortium 'Stronger on your own feet' to TK and MHW, The Netherlands Organization for Health Research and Development (ZonMw grants 917-86-319 to BBAdV, 916-86-016 to LELMV, 917-96-346 to AS and 907-00-365 to TK), the European Union under the 7th framework program (Gencodys HEALTH-F4-2010-241995 to BBAdV, HvB, ZA, AS and TK), the Dutch Brain Foundation (to DAK and BBAdV), the Hungarian Scientific Research Fund (K-82090 to ZA), and grants from the Jérôme Lejeune foundation and from the German Federal Ministry of Education and Research (BMBF funding to the German Mental Retardation Network, MRNET to AS).

Competing interests None.

Patient consent Obtained.

Ethics approval Local medical ethical committee.

Provenance and peer review Not commissioned; externally peer reviewed.

Web resources <http://decipher.sanger.ac.uk>; <http://www.ecaruca.net>

REFERENCES

- van Bokhoven H. Genetic and epigenetic networks in intellectual disabilities. *Ann Rev Genet* 2011;45:81–104.
- Kleefstra T, Kramer JM, Neveling K, Willemsen MH, Koemans TS, Vissers LE, Wissink-Lindhout W, Fencikova M, van den Akker WM, Kasri NN, Nillesen WM, Prescott T, Clark RD, Devriendt K, van Reeuwijk J, de Brouwer AP, Gilissen C, Zhou H, Brunner HG, Veltman JA, Schenck A, van Bokhoven H. Disruption of an

EHMT1-associated chromatin-modification module causes intellectual disability. *Am J Hum Genet* 2012;91:73–82.

- Ng SB, Bigham AW, Buckingham KJ, Hannibal MC, McMillin MJ, Gildersleeve HI, Beck AE, Tabor HK, Cooper GM, Mefford HC, Lee C, Turner EH, Smith JD, Rieder MJ, Yoshiura K, Matsumoto N, Ohta T, Niikawa N, Nickerson DA, Bamshad MJ, Shendure J. Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. *Nat Genet* 2010;42:790–3.
- Hoischen A, van Bon BW, Gilissen C, Arts P, van Lier B, Steehouwer M, de Vries P, de Reuver R, Wieskamp N, Mortier G, Devriendt K, Amorim MZ, Revencu N, Kidd A, Barbosa M, Turner A, Smith J, Oley C, Henderson A, Hayes IM, Thompson EM, Brunner HG, de Vries BB, Veltman JA. De novo mutations of SETBP1 cause Schinzel-Giedion syndrome. *Nat Genet* 2010;42:483–5.
- Hoischen A, van Bon BW, Rodriguez-Santiago B, Gilissen C, Vissers LE, de Vries P, Janssen I, van Lier B, Hastings R, Smithson SF, Newbury-Ecob R, Kjaergaard S, Goodship J, McGowan R, Bartholdi D, Rauch A, Peippo M, Cobben JM, Wiczorek D, Gillessen-Kaesbach G, Veltman JA, Brunner HG, de Vries BB. De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome. *Nat Genet* 2011;43:729–31.
- Sirmaci A, Spiliopoulos M, Brancati F, Powell E, Duman D, Abrams A, Bademci G, Agolini E, Guo S, Konuk B, Kavaz A, Blanton S, Digilio MC, Dallapiccola B, Young J, Zuchner S, Tekin M. Mutations in ANKRD11 cause KBG syndrome, characterized by intellectual disability, skeletal malformations, and macrodontia. *Am J Hum Genet* 2011;89:289–94.
- Vissers LE, de Ligt J, Gilissen C, Janssen I, Steehouwer M, de Vries P, van Lier B, Arts P, Wieskamp N, del Rosario M, van Bon BW, Hoischen A, de Vries BB, Brunner HG, Veltman JA. A de novo paradigm for mental retardation. *Nat Genet* 2010;42:1109–12.
- de Ligt J, Willemsen MH, van Bon BW, Kleefstra T, Yntema HG, Kroes T, Vulto-van Silfhout AT, Koolen DA, de Vries P, Gilissen C, del Rosario M, Hoischen A, Scheffer H, de Vries BB, Brunner HG, Veltman JA, Vissers LE. Diagnostic exome sequencing in persons with severe intellectual disability. *N Engl J Med* 2012;367:1921–9.
- Rauch A, Wiczorek D, Graf E, Wieland T, Ende S, Schwarzmayr T, Albrecht B, Bartholdi D, Beygo J, Di Donato N, Dufke A, Cremer K, Hempel M, Horn D, Hoyer J, Joset P, Röpke A, Moog U, Riess A, Thiel CT, Tzschach A, Wiesener A, Wohlleber E, Zweier C, Ekici AB, Zink AM, Rump A, Meisinger C, Grallert H, Sticht H, Schenck A, Engels H, Rappold G, Schröck E, Wieacker P, Riess O, Meitinger T, Reis A, Strom TM. Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study. *Lancet* 2012;380:1674–82.
- Willemsen MH, Vissers LE, Willemsen MA, van Bon BW, Kroes T, de Ligt J, de Vries BB, Schoots J, Lugtenberg D, Hamel BC, van Bokhoven H, Brunner HG, Veltman JA, Kleefstra T. Mutations in DYNC1H1 cause severe intellectual disability with neuronal migration defects. *J Med Genet* 2012;49:179–83.
- Feng Q, Zhang Y. The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. *Genes Dev* 2011;15:827–32.
- Brackertz M, Gong Z, Leers J, Renkawitz R. p66alpha and p66beta of the Mi-2/NuRD complex mediate MBD2 and histone interaction. *Nucl Acids Res* 2006;34:397–406.
- Tsurusaki Y, Okamoto N, Ohashi H, Kosho T, Imai Y, Hibi-Ko Y, Kaname T, Naritomi K, Kawame H, Wakui K, Fukushima Y, Homma T, Kato M, Hiraki Y, Yamagata T, Yano S, Mizuno S, Sakazume S, Ishii T, Nagai T, Shiina M, Ogata K, Ohta T, Niikawa N, Miyatake S, Okada I, Mizuguchi T, Doi H, Saitsu H, Miyake N, Matsumoto N. Mutations affecting components of the SWI/SNF complex cause Coffin-Siris syndrome. *Nat Genet* 2012;44:376–8.
- Kon C, Cadigan KM, da Silva SL, Nusse R. Developmental roles of the Mi-2/NuRD-associated protein p66 in *Drosophila*. *Genetics* 2005;169:2087–100.
- Dietzl G, Chen D, Schnorrrer F, Su KC, Barinova Y, Fellner M, Gasser B, Kinsey K, Oppel S, Scheiblauer S, Couto A, Marra V, Keleman K, Dickson BJ. A genome-wide transgenic RNAi library for conditional gene inactivation in *Drosophila*. *Nature* 2007;448:151–6.
- Sharma P, Keane J, O'Kane CJ, Asztalos Z. Automated measurement of *Drosophila* jump reflex habituation and its use for mutant screening. *J Neurosci Meth* 2009;182:43–8.
- Asztalos Z, Arora N, Tully T. Olfactory jump reflex habituation in *Drosophila* and effects of classical conditioning mutations. *J Neurogenet* 2007;21:1–18.
- Kramer JM, Kochinke K, Oortveld MA, Marks H, Kramer D, de Jong EK, Asztalos Z, Westwood JT, Stunnenberg HG, Sokolowski MB, Keleman K, Zhou H, van Bokhoven H, Schenck A. Epigenetic regulation of learning and memory by *Drosophila* EHMT1/G9a. *PLoS Biol* 2011;9:e1000569.
- Koh YH, Gramates LS, Budnik V. *Drosophila* larval neuromuscular junction: molecular components and mechanisms underlying synaptic plasticity. *Microsc Res Tech* 2000;49:14–25.
- Liu Z, Huang Y, Zhang Y, Chen D, Zhang YQ. *Drosophila* Acyl-CoA synthetase long-chain family member 4 regulates axonal transport of synaptic vesicles and is required for synaptic development and transmission. *J Neurosci* 2011;31:2052–63.
- Schenck A, Bardoni B, Langmann C, Harden N, Mandel JL, Giangrande A. CYFIP1/Sra-1 controls neuronal connectivity in *Drosophila* and links the Rac1 GTPase pathway to the fragile X protein. *Neuron* 2003;38:887–98.

- 22 Zweier C, de Jong EK, Zweier M, Orrico A, Ousager LB, Collins AL, Bijlsma EK, Oortveld MA, Ekici AB, Reis A, Schenck A, Rauch A. CNTNAP2 and NRXN1 are mutated in autosomal-recessive Pitt-Hopkins-like mental retardation and determine the level of a common synaptic protein in *Drosophila*. *Am J Hum Genet* 2009;85:655–66.
- 23 Koolen DA, Kramer JM, Neveling K, Nillesen WM, Moore-Barton HL, Elmslie FV, Toutain A, Amiel J, Malan V, Tsai AC, Cheung SW, Gilissen C, Verwiel ET, Martens S, Feuth T, Bongers EM, de Vries P, Scheffer H, Vissers LE, de Brouwer AP, Brunner HG, Veltman JA, Schenck A, Yntema HG, de Vries BB. Mutations in the chromatin modifier gene KANSL1 cause the 17q21.31 microdeletion syndrome. *Nat Genet* 2012;44:639–41.
- 24 Koolen DA, Sharp AJ, Hurst JA, Firth HV, Knight SJ, Goldenberg A, Saugier-Verber P, Pfundt R, Vissers LE, Destrée A, Grisart B, Rooms L, Van der Aa N, Field M, Hackett A, Bell K, Nowaczyk MJ, Mancini GM, Poddighe PJ, Schwartz CE, Rossi E, De Gregori M, Antonacci-Fulton LL, McLellan MD II, Garrett JM, Wiechert MA, Miner TL, Crosby S, Ciccone R, Willatt L, Rauch A, Zenker M, Aradhya S, Manning MA, Strom TM, Wagenstaller J, Krepischi-Santos AC, Vianna-Morgante AM, Rosenberg C, Price SM, Stewart H, Shaw-Smith C, Brunner HG, Wilkie AO, Veltman JA, Zuffardi O, Eichler EE, de Vries BB. Clinical and molecular delineation of the 17q21.31 microdeletion syndrome. *J Med Genet* 2008;45:710–20.
- 25 Santen GW, Aten E, Sun Y, Almomani R, Gilissen C, Nielsen M, Kant SG, Snoeck IN, Peeters EA, Hilhorst-Hofstee Y, Wessels MW, den Hollander NS, Ruivenkamp CA, van Ommen GJ, Breuning MH, den Dunnen JT, van Haeringen A, Kriek M. Mutations in SWI/SNF chromatin remodeling complex gene ARID1B cause Coffin-Siris syndrome. *Nat Genet* 2012;44:379–80.
- 26 Van Houdt JK, Nowakowska BA, Sousa SB, van Schaik BD, Seuntjens E, Avonce N, Sifrim A, Abdul-Rahman OA, van den Boogaard MJ, Bottani A, Castori M, Cormier-Daire V, Deardorff MA, Filges I, Fryer A, Fryns JP, Gana S, Garavelli L, Gillessen-Kaesbach G, Hall BD, Horn D, Huylebroeck D, Klapceki J, Krajewska-Walasek M, Kuechler A, Lines MA, Maas S, Macdermot KD, McKee S, Magee A, de Man SA, Moreau Y, Morice-Picard F, Obersztyn E, Pilch J, Rosser E, Shannon N, Stolte-Dijkstra J, Van Dijk P, Vilain C, Vogels A, Wakeling E, Wieczorek D, Wilson L, Zuffardi O, van Kampen AH, Devriendt K, Hennekam R, Vermeesch JR. Heterozygous missense mutations in SMARCA2 cause Nicolaides-Baraitser syndrome. *Nat Genet* 2012;44:445–9.
- 27 Wolff D, Ende S, Azzarello-Burri S, Hoyer J, Zweier M, Schanze I, Schmitt B, Rauch A, Reis A, Zweier C. In-frame deletion and missense mutations of the C-terminal helicase domain of SMARCA2 in three patients with Nicolaides-Baraitser Syndrome. *Mol Syndromol* 2012;6:237–44.
- 28 Kleefstra T, Brunner HG, Amiel J, Oudakker AR, Nillesen WM, Magee A, Geneviève D, Cormier-Daire V, van Esch H, Fryns JP, Hamel BC, Systersmans EA, de Vries BB, van Bokhoven H. Loss-of-function mutations in euchromatin histone methyl transferase 1 (EHMT1) cause the 9q34 subtelomeric deletion syndrome. *Am J Hum Genet* 2006;79:370–7.
- 29 Jones WD, Dafou D, McEntagart M, Woollard WJ, Elmslie FV, Holder-Espinasse M, Irving M, Saggat AK, Smithson S, Trembath RC, Deshpande C, Simpson MA. De novo mutations in MLL cause Wiedemann-Steiner syndrome. *Am J Hum Genet* 2012;91:358–64.
- 30 Clayton-Smith J, O'Sullivan J, Daly S, Bhaskar S, Day R, Anderson B, Voss AK, Thomas T, Biesecker LG, Smith P, Fryer A, Chandler KE, Kerr B, Tassabehji M, Lynch SA, Krajewska-Walasek M, McKee S, Smith J, Sweeney E, Mansour S, Mohammed S, Donnai D, Black G. Whole-exome-sequencing identifies mutations in histone acetyltransferase gene KAT6B in individuals with the Say-Barber-Biesecker variant of Ohdo syndrome. *Am J Hum Genet* 2011;89:675–81.
- 31 Marino S, Nusse R. Mutants in the mouse NuRD/Mi2 component P66alpha are embryonic lethal. *PLoS ONE* 2007;2:e519.32.
- 32 Marhold J, Brehm A, Kramer K. The *Drosophila* methyl-DNA binding protein MBD2/3 interacts with the NuRD complex via p55 and Mi-2. *BMC Mol Biol* 2004;5:20.